Bumol TF - Search Results

1

Expression levels of protein kinase C-alpha in non-small-cell lung cancer.

Lahn M, Su C, Li S, Chedid M, Hanna KR, Graff JR, Sandusky GE, Ma D, Niyikiza C, Sundell KL, John WJ, Giordano TJ, Beer DG, Paterson BM, Su EW, Bumol TF. Lahn M, et al. Among authors: bumol tf. Clin Lung Cancer. 2004 Nov;6(3):184-9. doi: 10.3816/clc.2004.n.032. Clin Lung Cancer. 2004. PMID: 15555220

2

Protein kinase C alpha expression in breast and ovarian cancer.

Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, Bumol TF. Lahn M, et al. Among authors: bumol tf. Oncology. 2004;67(1):1-10. doi: 10.1159/000080279. Oncology. 2004. PMID: 15459489 Review.

3

Protein kinase C-alpha in prostate cancer.

Lahn M, Sundell K, Gleave M, Ladan F, Su C, Li S, Ma D, Paterson BM, Bumol TF. Lahn M, et al. Among authors: bumol tf. BJU Int. 2004 May;93(7):1076-81. doi: 10.1111/j.1464-410X.2003.04784.x. BJU Int. 2004. PMID: 15142167 Review. No abstract available.

4

The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.

Apelgren LD, Bailey DL, Fouts RL, Short L, Bryan N, Evans GF, Sandusky GE, Zuckerman SH, Glasebrook A, Bumol TF. Apelgren LD, et al. Among authors: bumol tf. Cell Immunol. 1996 Oct 10;173(1):55-63. doi: 10.1006/cimm.1996.0251. Cell Immunol. 1996. PMID: 8871601

5

Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA.

Strnad J, Hamilton AE, Beavers LS, Gamboa GC, Apelgren LD, Taber LD, Sportsman JR, Bumol TF, Sharp JD, Gadski RA. Strnad J, et al. Among authors: bumol tf. Cancer Res. 1989 Jan 15;49(2):314-7. Cancer Res. 1989. PMID: 2463074

6

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. Dantzig AH, et al. Among authors: bumol tf. Cancer Res. 1996 Sep 15;56(18):4171-9. Cancer Res. 1996. PMID: 8797588

7

In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.

Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, Strnad J, Rittmann-Grauer L, DeHerdt SV, Bumol TF, et al. Starling JJ, et al. Among authors: bumol tf. Cancer Res. 1990 Dec 1;50(23):7634-40. Cancer Res. 1990. PMID: 1979247

8

The development and characterization of Vinca alkaloid-resistant Caco-2 human colorectal cell lines expressing mdr-1.

Hoskins J, DeHerdt SV, Moore RE, Bumol TF. Hoskins J, et al. Among authors: bumol tf. Int J Cancer. 1993 Feb 20;53(4):680-8. doi: 10.1002/ijc.2910530426. Int J Cancer. 1993. PMID: 8094716

9

The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.

Petersen BH, DeHerdt SV, Schneck DW, Bumol TF. Petersen BH, et al. Among authors: bumol tf. Cancer Res. 1991 May 1;51(9):2286-90. Cancer Res. 1991. PMID: 2015593 Clinical Trial.

10

Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.

Apelgren LD, Zimmerman DL, Briggs SL, Bumol TF. Apelgren LD, et al. Among authors: bumol tf. Cancer Res. 1990 Jun 15;50(12):3540-4. Cancer Res. 1990. PMID: 2340502

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters